Friday, October 23, 2020 9:07:04 PM
The company has a three-candidate pipeline led by a dual-targeted NK cell therapy that has a CD19 CAR and membrane-bound TNF-related apoptosis inducing ligand variant. This targets the death receptor 5 pathway [1]. Previously the death receptor 4 pathway, and both were going to be targeted for certain types.
The second candidate is an anti-CD38 CAR and will be given with a systemic anti-IL-6(R) mAb [2].
The third targets MUC-1 and there may be knock-out of genes encoding PD-1 [3], TIGIT [4], CD96 [5] and/or Siglec-7 [6]. Doing the same with a few others, such as CBL-B [7], IL-1R8 [8], and these [9] would help improve efficacy.
All allo (healthy donor) products will use a CD28 co-stim and soluble IL-15 (similar to this [10,11]). Also, they plan to increase trafficking to sites of disease [12-14].
However, cancer cells can develop resistance to the death receptor pathway(s) being targeted [15]. But there could be ways to overcome that [16].
Refs:
1 https://journals.lww.com/immunotherapy-journal/Abstract/2013/06000/Membrane_bound_TRAIL_Supplements_Natural_Killer.4.aspx
2 https://www.frontiersin.org/articles/10.3389/fendo.2018.00788/full
3 https://www.jacionline.org/article/S0091-6749(16)30360-8/fulltext
4 https://www.nature.com/articles/s41590-018-0132-0
5 https://www.nature.com/articles/nri3799
6 https://onlinelibrary.wiley.com/doi/full/10.1111/sji.12455
7 https://www.nature.com/articles/nature12998
8 https://www.nature.com/articles/nature24293
9 https://cancerres.aacrjournals.org/content/80/16_Supplement/891
10 https://www.nature.com/articles/leu2017226
11 https://www.nejm.org/doi/full/10.1056/NEJMoa1910607
12 https://ashpublications.org/blood/article/132/Supplement%201/4547/275557/Providing-a-Homing-Receptor-for-CAR-Engineered-NK
13 https://link.springer.com/article/10.1007%2Fs00262-014-1629-5
14 https://link.springer.com/protocol/10.1007%2F978-1-4939-3684-7_19
15 https://www.nature.com/articles/onc2012164
16 https://ashpublications.org/blood/article/135/9/597/429647/Integrated-drug-profiling-and-CRISPR-screening
Recent NKTX News
- Nkarta to Participate in Upcoming Investor Conference • GlobeNewswire Inc. • 09/03/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/23/2024 08:30:04 PM
- Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights • GlobeNewswire Inc. • 08/14/2024 01:03:42 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:08:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:05:18 PM
- Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights • GlobeNewswire Inc. • 08/13/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 08:48:13 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 08:47:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 08:45:43 PM
- Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus • GlobeNewswire Inc. • 07/24/2024 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/16/2024 10:30:13 AM
- Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President • GlobeNewswire Inc. • 07/16/2024 10:01:00 AM
- Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications • GlobeNewswire Inc. • 06/27/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:10:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:07:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:07:22 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:04:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 08:22:58 PM
- Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors • GlobeNewswire Inc. • 06/13/2024 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:14:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:04:53 PM
- Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights • GlobeNewswire Inc. • 05/09/2024 08:01:00 PM
- Nkarta to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 04/03/2024 08:02:00 PM
- Nkarta Announces Pricing of $240 Million Underwritten Offering • GlobeNewswire Inc. • 03/25/2024 10:30:00 AM
- Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights • GlobeNewswire Inc. • 03/21/2024 08:01:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM